Shares of Celcuity, Inc. (NASDAQ:CELC – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $154.5455.
A number of equities analysts have issued reports on the company. Macquarie Infrastructure set a $160.00 target price on Celcuity in a research report on Thursday, May 28th. Craig Hallum reissued a “buy” rating and set a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. Stifel Nicolaus dropped their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Wells Fargo & Company cut their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $177.00 price objective on shares of Celcuity in a research note on Monday, August 17th.
View Our Latest Research Report on CELC
Institutional Trading of Celcuity
Celcuity Price Performance
Shares of NASDAQ CELC opened at $95.70 on Monday. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -22.26 and a beta of 0.19. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The stock’s 50-day simple moving average is $94.58 and its 200-day simple moving average is $106.78.
Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, equities analysts anticipate that Celcuity will post -4.75 earnings per share for the current fiscal year.
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Recommended Stories
- Five stocks we like better than Celcuity
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
